Cost-effectiveness of denosumab versus zoledronic acid (za) for the prevention of skeletal-related events (SRE) in patient...
Upcoming SlideShare
Loading in...5
×

Cost-effectiveness of denosumab versus zoledronic acid (za) for the prevention of skeletal-related events (SRE) in patients with bone metastases (BM) from castration-resistant prostate cancer (CRPC) Sweden, Switzerland and Portugal.

267

Published on

Lothgren M, Bracco A, Lundkvist J, Biteeva I, Schwenkglenks M, Cristino J, Pereira J, Northridge K, Halperin M, Macarios D, Chung K, Danese MD. Cost-effectiveness of denosumab versus zoledronic acid (za) for the prevention of skeletal-related events (SRE) in patients with bone metastases (BM) from castration-resistant prostate cancer (CRPC) Sweden, Switzerland and Portugal. Presented at the 9th Annual HTAi meeting 2012 (Spain Bilbao 25-27 June 2012). Abstract published in Gaceta Sanitaria 2012, Vol. 26 Especial Congreso 2 – Junio 2012: 282.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
267
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

×